Prevalence of lifestyle characteristics in glucocorticoid users and non-users: a Danish population-based cross-sectional study

Prevalence of lifestyle characteristics in glucocorticoid users and non-users: a Danish population-based cross-sectional study

ObjectivesLifestyle may affect observed associations between glucocorticoid use and adverse events. This study aimed to investigate whether lifestyle differ according to use of systemic glucocorticoids.DesignPopulation-based cross-sectional study.SettingThe Central Denmark Region.Participants30 245...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ open 2019-10, Vol.9 (10), p.e030780
Hauptverfasser: Laugesen, Kristina, Petersen, Irene, Pedersen, Lars, Breinholt Larsen, Finn, Jørgensen, Jens Otto Lunde, Sørensen, Henrik Toft
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Aged, 80 and over
alcohol drinking
Alcohol Drinking - epidemiology
Body Mass Index
Case-Control Studies
Chronic obstructive pulmonary disease
Cross-Sectional Studies
Denmark - epidemiology
diet
Diet - statistics & numerical data
Drug dosages
Epidemiology
Exercise
Female
glucocorticoids
Glucocorticoids - therapeutic use
Health risk assessment
Humans
Male
Middle Aged
Obesity
Obesity - epidemiology
Overweight - epidemiology
Population-based studies
Prevalence
smoking
Smoking - epidemiology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ObjectivesLifestyle may affect observed associations between glucocorticoid use and adverse events. This study aimed to investigate whether lifestyle differ according to use of systemic glucocorticoids.DesignPopulation-based cross-sectional study.SettingThe Central Denmark Region.Participants30 245 adults (≥25 years of age) who participated in a questionnaire-based public health survey in 2010.Outcome measuresSystemic glucocorticoid use was categorised as never use, current use (prescription redemption ≤90 days before completing the questionnaire), recent use (prescription redemption 91–365 days before completing the questionnaire), former use (prescription redemption >365 days before completing the questionnaire) and according to cumulative dose expressed in prednisolone equivalents (
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2019-030780